all stories

BeOne Medicines Q2 Earnings Call Highlights

Steadysingle sourceOne outlet reported this, in 2 reports over 2 days - no second voice in this corpus.
Wed, 5 August 2026Sat, 8 August 2026

What it is about

Aaron RosenbergJohn OylerAmit AgarwalXiao Dong WangDevelopment Lai WangGlobal Head Of ResearchBeone Medicines LtdSwitzerlandChinaNew Jersey, United StatesChan Henry LeeJpmorgan Chase CoBeone Medicines Company ProfileNasdaqZacks ResearchBarclaysSecurities Exchange CommissionMan GroupAmerica

Who published it, and when

original reportfirst to report
themarketsdaily.com1 original report1 original report
5 Aug, 19:05over 3 days8 Aug, 08:12

How it spread - 2 original reports

  1. Wed, 5 August 2026

    1 report
    • themarketsdaily.com19:05first to report

      BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets. Chief Executive Officer John Oyler said the company raised its 2026 guidance for revenue and […]

  2. Sat, 8 August 2026

    1 report
    • themarketsdaily.com08:12

      BeOne Medicines (NASDAQ:ONC – Get Free Report) had its price objective raised by stock analysts at Citizens Jmp from $396.00 to $405.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 16.29% from […]

One email a week

The stories everytrace watched stay alive - how many independent outlets carried each one, and how long it lasted. No daily digest, no breaking-news alerts.